Crossmark

Pathophysiology, echocardiographic evaluation, biomarker findings, and prognostic implications of septic cardiomyopathy: a review of the literature

Crossref DOI link: https://doi.org/10.1186/s13054-018-2043-8

Published Online: 2018-05-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ehrman, Robert R.

Sullivan, Ashley N.

Favot, Mark J.

Sherwin, Robert L.

Reynolds, Christian A.

Abidov, Aiden

Levy, Phillip D.
License Information

Text and Data Mining valid from 2018-05-04
More Information

Article History

Received: 4 January 2018

Accepted: 16 April 2018

First Online: 4 May 2018

Competing interests

: PL received consulting fees from the following companies/organizations: Novartis Pharmaceuticals, Cardiorentis Inc., Trevena Inc., Apex Innovations, Roche Diagnostics, Siemens, Shire, Sciex. PL received consulting fees from the following institutions/organizations: Novartis Pharmaceuticals, Cardiorentis Inc., Trevena Inc., Amgen, BMS, Edwards Lifesciences, AHRQ (1 R01 HS025411), NHLBI (1 R34 HL136986 and 5 R01 HL127215), NIH Admin (1 U24 NS100680), PCORI (FC14-1409-21,656), Blue Cross Blue Shield of MI Foundation. The other authors have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.